Streetbeat News

Price Targets

IBTA

Ibotta, Inc. (NYSE:IBTA) reported a year-over-year decrease in Q2 adjusted EPS and issued Q3 revenue guidance below estimates. Despite beating Q2 sales estimates, shares dipped 24.6%. Multiple analysts lowered their price targets while maintaining their ratings.

Portfolio Pulse from Avi Kapoor

August 14, 2024 | 7:05 pm

NCNO

Analysts' ratings for Ncino (NASDAQ:NCNO) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $39.25, reflecting a 2.51% rise. Key analysts have adjusted their ratings and price targets, with some raising and others maintaining their positions. Ncino has shown positive revenue growth and strong financial health indicators, despite being smaller in market capitalization compared to peers.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 7:00 pm

BEEM

Beam Global shares are trading lower after the company reported worse-than-expected Q2 financial results. B. Riley Securities also lowered its price target on the stock from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:54 pm

OUST

Ouster Inc. (NYSE: OUST) reported weaker-than-expected Q2 sales, leading to a 27.7% drop in its stock price. Despite beating EPS estimates, the company missed revenue expectations and provided lower-than-expected Q3 revenue guidance. Analysts have adjusted their price targets downward.

Portfolio Pulse from Avi Kapoor

August 14, 2024 | 6:54 pm

AWH

Alliance Global Partners maintains a Buy rating on Aspira Womens Health (NASDAQ:AWH) but lowers the price target from $7 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:49 pm

CDTX

HC Wainwright & Co. has upgraded Cidara Therapeutics (NASDAQ:CDTX) from Neutral to Buy, with a new price target of $24.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:46 pm

MRNS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Marinus Pharma (NASDAQ:MRNS) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:42 pm

VALN

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Valneva (NASDAQ:VALN) and maintained a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:40 pm

CMRX

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Chimerix (NASDAQ:CMRX) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:39 pm

SE

BofA Securities analyst Sachin Salgaonkar reiterated a Buy rating on Sea Limited (NYSE:SE), raising the price target to $84 from $77. Sea Limited reported a 23% YoY revenue growth for Q2, beating estimates. The company is expected to benefit from e-commerce growth in Southeast Asia and expansion into Brazil. The analyst revised FY24/25 EPS estimates and target multiples for gaming and Shopee, indicating improved business momentum.

Portfolio Pulse from Nabaparna Bhattacharya

August 14, 2024 | 6:35 pm